Clinical Trial Update: Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve Adults [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in vaccine-naïve adults has completed; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease

Drugs mentioned

• 20-valent pneumococcal conjugate vaccine (pneumococcal conjugate vaccine, 20-valent)

Snippet

Sponsor: Pfizer | Conditions: Pneumococcal Disease | Phase 3 | Status: COMPLETED | Results posted: 2020-12-29